DHPA

  • Home
  • About Us
    • Leadership
      • Executive Committee
      • Board Members
    • DHPA Members
    • Contact Us
    • Join Us
  • Advocacy
    • Patient Access to Independent GI Care
      • Colorectal Cancer Screening
    • Diversity Equity and Inclusion
    • Modernizing the Stark Law
    • Saving the IOASE
    • Pathology Services Utilization
  • Resources
    • CRC Screening
    • Independent GI Careers
    • Research
    • Fact Sheets
    • Letters to Policymakers
    • Leadership Webinar Series
  • Newsroom
    • Press Releases
    • DHPA in the News
    • GI News Round Up
  • Take Action

February 15, 2022

DHPA Requests Safe Harbor for Copay Coupons for Drugs with no Lower-Cost Alternative

DHPA was among 18 provider and patient advocacy groups that signed onto a letter requesting that the Office of the Inspector General (OIG) issue new guidance indicating that manufacturer copay assistance to federal health program beneficiaries is a violation of the Anti-Kickback Statute when there is a less expensive and equally effective generic or interchangeable biosimilar available.

The OIG has been consistent in its position that drug company copay coupons for brand drugs used in federal health programs constitute a violation of the Anti-Kickback Statute in situations where less expensive and equally effective alternatives exist, but has not directly addressed whether a coupon is an inducement in situations where less expensive and equally effective alternatives do not exist – in other words, in cases where the brand drug is the only available treatment.

In the letter, the groups wrote, “In such cases, the potential for inducement does not exist, therefore, the sound policy rationale underlying the prohibition of these coupons for brands with generic alternatives cannot apply. However, since a regulated industry attempting to stay within legal and regulatory bounds will usually answer open questions with the widest possible interpretation of statute and guidance, the result is that pharmaceutical companies currently will not offer any cost-sharing assistance to Medicare and Medicaid beneficiaries for any medication. In situations where no lower-cost alternative exists, this lack of copay assistance does not result in a patient taking the generic versus the brand. Rather, it can result in a patient not being treated at all to manage their condition(s).”

Click here to read the full letter >>

 

Filed Under: Advocacy, Letters to Policymakers, Newsroom, Protecting Patient Access to Integrated GI Care in the Independent Setting, Resources

Member Spotlight

Adult Gastroenterology Associates is a single-specialty GI and hepatology practice serving Tulsa and much of Northeastern Oklahoma, with physicians who specialize in colon cancer screening, treatment of GERD, IBD, and treatment of diseases of the liver and pancreas.

Learn more at:
www.tulsagastro.com

Become a Member

    Is your practice interested in promoting and preserving accessible, high quality and cost-efficient care in the independent GI medical setting? Contact us today about joining DHPA.

    Recent News

    • The Value of Colonoscopy: The Gold Standard in Colorectal Cancer Screening (Video)

    • Colorectal Cancer: Am I at Risk? (Video)

    • The Value of Colonoscopy (Infographic)

    • Colorectal Cancer: Am I at Risk? (Infographic)

    • Value of Colonoscopy Spanish Translation (Infographic)

    • Colorectal Cancer: Am I at Risk? Spanish Translation (Infographic)

    • DHPA Recommends MACRA Improvements to Bipartisan Group of U.S. Representatives

    • New Study in Gastro Journal: GI Patients Consider Telehealth to be the Same as In-Person Visits

    • DHPA Comment Letter on OPPS/ASC Proposed Rule for Calendar Year 2023

    Digestive Health Physicians Association, Inc.
    10770 Columbia Pike, Suite 400
    Silver Spring, Maryland, 20901
    © 2020 DHPA

    Follow @DHPAnews
    Tweets by DHPAnews

    Copyright © 2023 · Executive Pro Theme on Genesis Framework · WordPress · Log in